GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
Final decision from the European Commission is anticipated within the coming months
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Subscribe To Our Newsletter & Stay Updated
